Werner syndrome RecQ helicase-IN-3

Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC 50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity In Vitro Werner syndrome RecQ helicase-IN-3 (example 96) (0-10 µM; 8-20 days) shows antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SW48, DLD1 WRN-KO cells Concentration: 0-10 µM Incubation Time: 8-20 days Result: Showed antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. In Vivo Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) Dosage: 120 mg/kg Administration: P.o.; daily for 22 days Result: Inhibited tumor growth. Form:Solid IC50& Target:IC 50 : 0.06 µM (WRN)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet